Increase in the number of clinical trials and rise in the frequency of neurodegenerative diseases are the factors augmenting the induced pluripotent stem cells market.
The advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) such as higher rate of apoptosis and reduced risks of low-level DNA damage are making them a preferable choice.
The companies operating in the induced pluripotent stem cells market are adopting 3D cell culture technology, which better imitates natural cellular environment in human body in comparison with conventional 2D cell cultures. They are also focusing on developing xeno-free solutions for differentiation and maintenance of stem cells.
Induced pluripotent stem cells (iPSCs) are a kind of pluripotent stem cells that could be generated on direct basis from the adult cells. Their discovery has brought about a creative disruption in stem cell research as it outshines various ethical issues linked with embryonic stem cells.
iPSCs are generated via expression of genes and factors that are capable of reprogramming a normal adult differentiated somatic cell into an embryonic stem cell-like pluripotent state. The process lets scientists generate disease-specific and patient stem cells without causing any damage to human embryos.
The two types of iPSCs are virus-based and non-virus-based. The former ones use of lentiviruses and retroviruses in order to deliver reprogramming genes into the adult cells.
The method is efficient but risks formation of tumor and modification of genes. The latter one uses molecules such as chemicals and proteins for generating iPSCs without touching the host genome. It’s less efficient but safer.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Induced pluripotent stem cells market has turned out to be one of the promising avenues regarding development of new treatments targeting underlying reasons of such incurable diseases such as neurodegenerative diseases.
iPSCs are reported to provide a potential alternative with regards to human embryonic stem cells in order to achieve personalized cell therapies and developing various disease models for the drug discovery procedures.
As per an article published by the WHO in 2022, more than 55 million individuals lived with dementia, with almost 10 million novel cases emerging very single year.
It further states that Alzheimer’s disease alone has affected over 30 million people across the globe. A noticeable rise in geriatric population worldwide, especially in the developed countries, is responsible for increasing cases of neurodegenerative conditions.
Need to start with treatment of neurodegenerative diseases on timely basis is thus accelerating the induced pluripotent stem cells market demand.
An increasing number of pharmaceutical companies and research institutes are conducting various clinical trials in order to evaluate iPSCS’ therapeutic potential. As per the WHO, more than 300 iPSC clinical trials were registered worldwide between 2020 and 2022.
They targeted various conditions such as Parkinson’s disease, macular degeneration, diabetes, and heart disease. It further states that the countries having the most registered iPSC trials during this period were Japan, the U.K., China, and U.S. Such trials are into investigation of safety and efficacy of usage of iPSC-derived cells for drug testing, transplantation, and disease modeling.
The government agencies such as the National Institute for Health Research (U.K.) and the National Institutes of Health (NIH) (U.S.) are supporting various iPSC projects via funding. For instance, NIH, in 2023, invested US$ 79 Mn in research related to iPSC in 2021 as per its yearly report.
Continual clinical trials followed by monetary help through various agencies is thus driving the induced pluripotent stem cells market growth.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest induced pluripotent stem cells market scenario, North America dominated the reprogrammed stem cells landscape and the dominance is expected to continue during the forecast period. This is attributed to the region witnessing a sizable number of trials for iPSCs.
As of now, there are over 58 clinical trials underway. Besides, institutes such as National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS), California Institute for regenerative Medicine (CIRM), and others extend support to the induced pluripotent stem cells (iPSCs)-related research activities.
Asia Pacific’s significant induced pluripotent stem cells market share is ascribed to cost-effective stem cell-based research, betterment of the healthcare plans, expanding economies, and rise in awareness regarding potential of the personalized treatments.
In June 2023, REPROCELL, Inc. announced launching a paid service called Pharmacology-AI. The company has also collaborated with HNCDI for developing EXCELERATE, an ML platform that streamlines and expedites processing information obtained from studies related to drug creation.
The induced pluripotent stem cells market manufacturers are engaging in inorganic modes of expansion to strengthen their position.
For instance, in January 2022, Century Therapeutics entered into a collaboration and license agreement with Bristol-Myers Squibb with the objective of developing and commercializing close to four induced pluripotent stem cell-derived, engineered natural killer cell and/or T-cell programs for solid tumors and hematologic malignancies.
Axol Bioscience, Cynata Therapeutics Limited, Evotec SE, Fate Therapeutics, FUJIFILM Cellular Dynamics, Inc., Ncardia, LizarBio Therapeutics, REPROCELL Global, Sumitomo Dainippon Pharma Company Limited, Takara Bio USA, Inc., Thermo Fisher Scientific, and Vertex Pharmaceuticals are some of the key players covered in the Induced pluripotent stem cells market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 1.7 Bn |
| Market Forecast (Value) in 2034 | US$ 4.6 Bn |
| Growth Rate (CAGR) | 9.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 1.7 Bn in 2023
It is projected to grow at a CAGR of 9.4% from 2024 to 2034
Growing prevalence of neurodegenerative diseases and rise in the number of clinical trials
Diagnostic centers segment accounted for the largest share in 2023
North America was the dominant region in 2023
Axol Bioscience, Cynata Therapeutics Limited, Evotec SE, Fate Therapeutics, FUJIFILM Cellular Dynamics, Inc., Ncardia, LizarBio Therapeutics, REPROCELL Global, Sumitomo Dainippon Pharma Company Limited, Takara Bio USA, Inc., Thermo Fisher Scientific, and Vertex Pharmaceuticals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Induced Pluripotent Stem Cells Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Induced Pluripotent Stem Cells Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Cell Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cell Type, 2020-2034
6.3.1. Hepatocytes
6.3.2. Fibroblasts
6.3.3. Keratinocytes
6.3.4. Others (Neurons, etc.)
6.4. Market Attractiveness Analysis, by Cell Type
7. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020-2034
7.3.1. Drug Development
7.3.2. Regenerative Medicine
7.3.3. Toxicity Testing
7.3.4. Tissue Engineering
7.3.5. Cell Therapy
7.3.6. Disease Modeling
7.4. Market Attractiveness Analysis, by Application
8. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Pharmaceutical & Biotechnology Companies
8.3.4. Contract Research Organizations
8.3.5. Others (Academic & Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Induced Pluripotent Stem Cells Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Cell Type, 2020-2034
10.3.1. Hepatocytes
10.3.2. Fibroblasts
10.3.3. Keratinocytes
10.3.4. Others (Neurons, etc.)
10.4. Market Value Forecast, by Application, 2020-2034
10.4.1. Drug Development
10.4.2. Regenerative Medicine
10.4.3. Toxicity Testing
10.4.4. Tissue Engineering
10.4.5. Cell Therapy
10.4.6. Disease Modeling
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Diagnostic Centers
10.5.3. Pharmaceutical & Biotechnology Companies
10.5.4. Contract Research Organizations
10.5.5. Others (Academic & Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Cell Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Induced Pluripotent Stem Cells Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Cell Type, 2020-2034
11.3.1. Hepatocytes
11.3.2. Fibroblasts
11.3.3. Keratinocytes
11.3.4. Others (Neurons, etc.)
11.4. Market Value Forecast, by Application, 2020-2034
11.4.1. Drug Development
11.4.2. Regenerative Medicine
11.4.3. Toxicity Testing
11.4.4. Tissue Engineering
11.4.5. Cell Therapy
11.4.6. Disease Modeling
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Pharmaceutical & Biotechnology Companies
11.5.4. Contract Research Organizations
11.5.5. Others (Academic & Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Cell Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Induced Pluripotent Stem Cells Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Cell Type, 2020-2034
12.3.1. Hepatocytes
12.3.2. Fibroblasts
12.3.3. Keratinocytes
12.3.4. Others (Neurons, etc.)
12.4. Market Value Forecast, by Application, 2020-2034
12.4.1. Drug Development
12.4.2. Regenerative Medicine
12.4.3. Toxicity Testing
12.4.4. Tissue Engineering
12.4.5. Cell Therapy
12.4.6. Disease Modeling
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Pharmaceutical & Biotechnology Companies
12.5.4. Contract Research Organizations
12.5.5. Others (Academic & Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Cell Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Induced Pluripotent Stem Cells Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Cell Type, 2020-2034
13.3.1. Hepatocytes
13.3.2. Fibroblasts
13.3.3. Keratinocytes
13.3.4. Others (Neurons, etc.)
13.4. Market Value Forecast, by Application, 2020-2034
13.4.1. Drug Development
13.4.2. Regenerative Medicine
13.4.3. Toxicity Testing
13.4.4. Tissue Engineering
13.4.5. Cell Therapy
13.4.6. Disease Modeling
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Pharmaceutical & Biotechnology Companies
13.5.4. Contract Research Organizations
13.5.5. Others (Academic & Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Cell Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Induced Pluripotent Stem Cells Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Cell Type, 2020-2034
14.3.1. Hepatocytes
14.3.2. Fibroblasts
14.3.3. Keratinocytes
14.3.4. Others (Neurons, etc.)
14.4. Market Value Forecast, by Application, 2020-2034
14.4.1. Drug Development
14.4.2. Regenerative Medicine
14.4.3. Toxicity Testing
14.4.4. Tissue Engineering
14.4.5. Cell Therapy
14.4.6. Disease Modeling
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Pharmaceutical & Biotechnology Companies
14.5.4. Contract Research Organizations
14.5.5. Others (Academic & Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Cell Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Axol Bioscience
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Cynata Therapeutics Limited
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Evotec SE
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Fate Therapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. FUJIFILM Cellular Dynamics, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Ncardia
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. LizarBio Therapeutics
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. REPROCELL Global
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Sumitomo Dainippon Pharma Company Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Takara Bio USA, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Thermo Fisher Scientific
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Vertex Pharmaceuticals
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
List of Tables
Table 01: Global Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 02: Global Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 03: Global Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 07: North America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 08: North America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 11: Europe Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 12: Europe Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 15: Asia Pacific Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 16: Asia Pacific Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 19: Latin America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 20: Latin America Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Cell Type, 2020-2034
Table 23: Middle East & Africa Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by Application, 2020-2034
Table 24: Middle East & Africa Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Induced Pluripotent Stem Cells Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Induced Pluripotent Stem Cells Market Revenue (US$ Bn), by Cell Type, 2023
Figure 03: Global Induced Pluripotent Stem Cells Market Value Share, by Cell Type, 2023
Figure 04: Global Induced Pluripotent Stem Cells Market Revenue (US$ Bn), by Application, 2023
Figure 05: Global Induced Pluripotent Stem Cells Market Value Share, by Application, 2023
Figure 06: Global Induced Pluripotent Stem Cells Market Revenue (US$ Bn), by End-user, 2023
Figure 07: Global Induced Pluripotent Stem Cells Market Value Share, by End-user, 2023
Figure 08: Global Induced Pluripotent Stem Cells Market Value Share, by Region, 2023
Figure 09: Global Induced Pluripotent Stem Cells Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 11: Global Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 13: Global Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 14: Global Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Induced Pluripotent Stem Cells Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Induced Pluripotent Stem Cells Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Induced Pluripotent Stem Cells Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 22: North America Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 23: North America Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 26: North America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Induced Pluripotent Stem Cells Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Induced Pluripotent Stem Cells Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 31: Europe Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 32: Europe Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 35: Europe Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Induced Pluripotent Stem Cells Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Induced Pluripotent Stem Cells Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 40: Asia Pacific Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 41: Asia Pacific Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 44: Asia Pacific Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Induced Pluripotent Stem Cells Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Induced Pluripotent Stem Cells Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 49: Latin America Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 50: Latin America Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 53: Latin America Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Induced Pluripotent Stem Cells Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Induced Pluripotent Stem Cells Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Induced Pluripotent Stem Cells Market Value Share Analysis, by Cell Type, 2023 and 2034
Figure 58: Middle East & Africa Induced Pluripotent Stem Cells Market Value Share Analysis, by Application, 2023 and 2034
Figure 59: Middle East & Africa Induced Pluripotent Stem Cells Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Induced Pluripotent Stem Cells Market Attractiveness Analysis, by Application, 2024-2034
Figure 62: Middle East & Africa Induced Pluripotent Stem Cells Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Induced Pluripotent Stem Cells Market
